Bionor Pharma's Universal Influenza Vaccine, Vacc-Flu, Targets Regions Shared by All Influenza A Strains; Reduces Serious Flu Symptoms by 25 Percent Over Standard Flu Vaccine in Animal Study
November 22, 2011 08:00 ET
|
Bionor Pharma
ARLINGTON, VA--(Marketwire - Nov 22, 2011) -
Summary of Findings
Bionor's Vacc-Flu could be "Universal," meaning that it could work on seasonal flu and also on...
Results From Phase IIB Placebo Controlled Study of Bionor Pharma's Vacc-4x Show Excellent Safety Profile, Statistically Significant Viral Load Reduction in Patients With HIV Who Suspend Antiretroviral Therapy
September 14, 2011 02:30 ET
|
BionorPharma
BANGKOK, THAILAND--(Marketwire - Sep 14, 2011) - Results from the furthest advanced study of a therapeutic vaccine candidate to treat people living with HIV/AIDS were announced at a news conference...
Bionor Pharma ASA Announces Exploratory Study of Its Lead Therapeutic HIV-Vaccine Candidate Vacc-4x in Combination With Leading Cancer Drug
August 25, 2011 08:00 ET
|
BionorPharma
OSLO, NORWAY--(Marketwire - Aug 25, 2011) - Bionor Pharma ASA (OSLO: BIONOR) announces plans to conduct an exploratory clinical study using Bionor Pharma's therapeutic HIV-vaccine candidate,...
Further Analysis of Vacc-4x Phase IIb Study Shows a Statistically Significant Reduction in Viral Load Over Placebo -- Previous Decision to Put Vacc-4x on Hold Has Been Reversed
November 18, 2010 09:05 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwire - November 18, 2010) - After further analyses of the international, randomized, double-blind, placebo-controlled multi-center phase IIb study of Bionor Pharma's (OSLO:...
Henrik Lund MD Ph.D, Former Global VP in Clinical Development at Astra Zeneca, Named New CEO of Bionor Pharma ASA
August 30, 2010 09:14 ET
|
BionorPharma
OSLO, NORWAY--(Marketwire - August 30, 2010) - Bionor Pharma (OSLO: BIONOR) today announced that Henrik Lund MD Ph.D, will take over the position of CEO from Trond Syvertsen effective from 1...
Two Thirds of Study Volunteers Respond to First-Ever "Re-Vaccination" of Vacc-4x, Bionor Pharma's Peptide-Based Therapeutic HIV-Vaccine
August 30, 2010 09:13 ET
|
BionorPharma
OSLO, NORWAY and WASHINGTON, DC--(Marketwire - August 30, 2010) -
Study Highlights: 25 volunteers from previously conducted Phase 2a trial were "re-vaccinated" with the vaccine after 7...
Researchers Present Findings Today at the XVIII International AIDS Conference, Vienna Austria
July 22, 2010 06:59 ET
|
BionorPharma
VIENNA, AUSTRIA--(Marketwire - July 22, 2010) - Researchers at Oslo University Hospital and Bionor Pharma's subsidiary, Bionor Immuno AS today presented results from a recently conducted...
UPDATE: NutriPharma ASA and Subsidiary Bionor Immuno AS Change Name to Bionor Pharma ASA; New Board Selected by Shareholders at Annual General Meeting
May 27, 2010 10:48 ET
|
BionorPharma
OSLO, NORWAY--(Marketwire - May 27, 2010) - Norwegian Nutri Pharma ASA (OSLO: NUT) and its subsidiary Bionor Immuno AS today announced that the parent Company Nutri Pharma ASA will now be known...